Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Sintilimab
Combination Product: TACE

First Posted Date: 2020-03-05

Last Posted Date: 2024-01-19

Lead Sponsor: Fudan University

Target Recruit Count: 25

Registration Number: NCT04297280

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant Chemotherapy

Phase 2

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2020-03-05

Last Posted Date: 2022-07-22

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT04297267

Locations: 🇨🇳
Cancer Hospital/ Institute, Fudan University, Shanghai, Shanghai, China

Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer

Not Applicable

Recruiting

Conditions: HER2-positive Breast Cancer

Interventions: Diagnostic Test: TCHP

First Posted Date: 2020-02-24

Last Posted Date: 2020-05-04

Lead Sponsor: Fudan University

Target Recruit Count: 94

Registration Number: NCT04281641

Locations: 🇨🇳
Shanghai Cancer Center, Fudan University, Shanghai, Shanghai, China

Next-generation Sequencing of Colorectal Cancer Somatic Cells to Guide Genetic Susceptibility Gene Mutations Screening.

Conditions: Hereditary Colorectal Cancer

First Posted Date: 2020-02-21

Last Posted Date: 2020-02-21

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT04280666

Locations: 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China

ScreenIng of Genetic Susceptibility Genes for Breast Cancer Patients in CHinese communiTies

Recruiting

Conditions: Genetic Susceptibility
Breast Cancer

First Posted Date: 2020-02-12

Last Posted Date: 2023-05-31

Lead Sponsor: Fudan University

Target Recruit Count: 5000

Registration Number: NCT04265937

Locations: 🇨🇳
Zhen Hu, Shanghai, Shanghai, China

Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma

Phase 2

Conditions: Melanoma Stage IIIB-IV

Interventions: Drug: Toripalimab

First Posted Date: 2020-01-30

Last Posted Date: 2020-01-30

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT04248387

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Effects of Docosahexanoic Acid on Neurocognitive Impairment in HIV-infected Patients

Phase 1

Conditions: Neurocognitive Impairment

Interventions: Drug: Docosahexaenoic acid (DHA) capsules
Dietary Supplement: Soy oil capsules

First Posted Date: 2020-01-27

Last Posted Date: 2020-01-27

Lead Sponsor: Fudan University

Target Recruit Count: 88

Registration Number: NCT04242004

Locations: 🇨🇳
Department of epidemiology, School of public health, Fudan University,, Shanghai, Shanghai, China

Study on Predictive Biomarkers of Neoadjuvant Chemoradiotherapy for Rectal Cancer

Conditions: Rectal Neoplasm Malignant Carcinoma
Chemoradiotherapy
Predictive Biomarkers
Adenocarcinoma
Neoadjuvant Therapy

Interventions: Radiation: Radiation
Drug: Capecitabine-Irinotecan Combination

First Posted Date: 2020-01-14

Last Posted Date: 2020-01-14

Lead Sponsor: Fudan University

Target Recruit Count: 250

Registration Number: NCT04227886

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer

Phase 2

Conditions: Stage IA Pancreatic Adenocarcinoma
Stage IB Pancreatic Adenocarcinoma
Stage IIA Pancreatic Adenocarcinoma
Stage IIB Pancreatic Adenocarcinoma

Interventions: Drug: nab-paclitaxel
Drug: tegafur
Drug: Gemcitabine

First Posted Date: 2020-01-03

Last Posted Date: 2020-06-30

Lead Sponsor: Fudan University

Target Recruit Count: 300

Registration Number: NCT04216758

Locations: 🇨🇳
Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University; 270 Dong An Road, Shanghai 200032, China, Shanghai, China

Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients

Phase 4

Conditions: Advanced Pancreatic Cancer

Interventions: Drug: Paclitaxel liposome
Drug: S-1

First Posted Date: 2020-01-03

Last Posted Date: 2020-01-03

Lead Sponsor: Fudan University

Target Recruit Count: 40

Registration Number: NCT04217096

Locations: 🇨🇳
Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University; 270 Dong An Road, Shanghai 200032, China, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy